

Proton Rahman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4560132/publications.pdf>

Version: 2024-02-01

132
papers

12,992
citations

61984

43
h-index

24258

110
g-index

138
all docs

138
docs citations

138
times ranked

13923
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational Landscape of Autism Spectrum Disorder Brain Tissue. <i>Genes</i> , 2022, 13, 207.	2.4	7
2	Public interest in unexpected genomic findings: a survey study identifying aspects of sequencing attitudes that influence preferences. <i>Journal of Community Genetics</i> , 2022, 13, 235-245.	1.2	1
3	Defining imaging sub-phenotypes of psoriatic arthritis: integrative analysis of imaging data and gene expression in a PsA patient cohort. <i>Rheumatology</i> , 2022, 61, 4952-4961.	1.9	3
4	Metabolomic signatures for the longitudinal reduction of muscle strength over 10 years. <i>Skeletal Muscle</i> , 2022, 12, 4.	4.2	3
5	Restricting Branched-Chain Amino Acids within a High-Fat Diet Prevents Obesity. <i>Metabolites</i> , 2022, 12, 334.	2.9	14
6	Psoriatic arthritis from a mechanistic perspective. <i>Nature Reviews Rheumatology</i> , 2022, 18, 311-325.	8.0	49
7	Endotypes of primary osteoarthritis identified by plasma metabolomics analysis. <i>Rheumatology</i> , 2021, 60, 2735-2744.	1.9	21
8	Phenylalanine Is a Novel Marker for Radiographic Knee Osteoarthritis Progression: The MOST Study. <i>Journal of Rheumatology</i> , 2021, 48, 123-128.	2.0	10
9	Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 604-616.	5.6	48
10	Association Between Epidemiological Factors and Nonresponders to Total Joint Replacement Surgery in Primary Osteoarthritis Patients. <i>Journal of Arthroplasty</i> , 2021, 36, 1502-1510.e5.	3.1	10
11	Genetic Epidemiology of Complex Phenotypes. <i>Methods in Molecular Biology</i> , 2021, 2249, 335-367.	0.9	3
12	Macrophage migration inhibitory factor may play a protective role in osteoarthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 59.	3.5	16
13	Insights into the pathogenesis of psoriatic arthritis from genetic studies. <i>Seminars in Immunopathology</i> , 2021, 43, 221-234.	6.1	9
14	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. <i>Rheumatology</i> , 2021, 60, 5337-5350.	1.9	18
15	Spinal mobility in radiographic axial spondyloarthritis: criterion concurrent validity of classic and novel measurements. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 464.	1.9	3
16	Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1022-1030.	0.9	18
17	Identifying Aspects of Public Attitudes Toward Whole Genome Sequencing to Inform the Integration of Genomics into Care. <i>Public Health Genomics</i> , 2021, 24, 229-240.	1.0	10
18	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1815-1823.	2.0	20

#	ARTICLE	IF	CITATIONS
19	Clinical and molecular significance of genetic loci associated with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101691.	3.3	5
20	Modelling the impact of travel restrictions on COVID-19 cases in Newfoundland and Labrador. <i>Royal Society Open Science</i> , 2021, 8, 202266.	2.4	15
21	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. <i>RMD Open</i> , 2021, 7, e001600.	3.8	18
22	Single-cell transcriptome identifies FCGR3B upregulated subtype of alveolar macrophages in patients with critical COVID-19. <i>IScience</i> , 2021, 24, 103030.	4.1	13
23	Metabolomic analysis coupled with extreme phenotype sampling identified that lysophosphatidylcholines are associated with multisite musculoskeletal pain. <i>Pain</i> , 2021, 162, 600-608.	4.2	17
24	Sphingomyelin is involved in multisite musculoskeletal pain: evidence from metabolomic analysis in 2 independent cohorts. <i>Pain</i> , 2021, 162, 1876-1881.	4.2	4
25	pathDIP 4: an extended pathway annotations and enrichment analysis resource for human, model organisms and domesticated species. <i>Nucleic Acids Research</i> , 2020, 48, D479-D488.	14.5	38
26	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. <i>Rheumatology</i> , 2020, 59, 1325-1334.	1.9	40
27	Metabolomics Signature for Non-Responders to Total Joint Replacement Surgery in Primary Osteoarthritis Patients: The Newfoundland Osteoarthritis Study. <i>Journal of Orthopaedic Research</i> , 2020, 38, 793-802.	2.3	23
28	P250-Effect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study. <i>Rheumatology</i> , 2020, 59, .	1.9	0
29	P277-Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. <i>Rheumatology</i> , 2020, 59, .	1.9	0
30	Is it safe to lift COVID-19 travel bans? The Newfoundland story. <i>Computational Mechanics</i> , 2020, 66, 1081-1092.	4.0	54
31	Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry. <i>BMJ Open</i> , 2020, 10, e036245.	1.9	2
32	Rho-GTPase pathways may differentiate treatment response to TNF-alpha and IL-17A inhibitors in psoriatic arthritis. <i>Scientific Reports</i> , 2020, 10, 21703.	3.3	5
33	Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1344.	1.2	50
34	Quantifying Differences in Heritability among Psoriatic Arthritis (PsA), Cutaneous Psoriasis (PsC) and Psoriasis vulgaris (PsV). <i>Scientific Reports</i> , 2020, 10, 4925.	3.3	20
35	Complexities in Genetics of Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2020, 22, 10.	4.7	23
36	Predicting therapeutic response through biomarker analysis in psoriatic arthritis, an example of precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 35-42.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1126-1136.	13.7	206
38	Public interest in whole genome sequencing and information needs: an online survey study. <i>Personalized Medicine</i> , 2020, 17, 283-293.	1.5	8
39	Differential correlation network analysis identified novel metabolomics signatures for non-responders to total joint replacement in primary osteoarthritis patients. <i>Metabolomics</i> , 2020, 16, 61.	3.0	12
40	Activation of The Phosphatidylcholine to Lysophosphatidylcholine Pathway Is Associated with Osteoarthritis Knee Cartilage Volume Loss Over Time. <i>Scientific Reports</i> , 2019, 9, 9648.	3.3	34
41	Serum lysophosphatidylcholines to phosphatidylcholines ratio is associated with symptomatic responders to symptomatic drugs in knee osteoarthritis patients. <i>Arthritis Research and Therapy</i> , 2019, 21, 224.	3.5	13
42	256â€¦Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2019, 58, .	1.9	3
43	Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC. <i>Frontiers in Genetics</i> , 2019, 10, 304.	2.3	6
44	Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab. <i>Rheumatology</i> , 2019, 58, 522-526.	1.9	8
45	The Genetics of Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2019, 95, 46-50.	2.0	38
46	A review of ustekinumab in the treatment of psoriatic arthritis. <i>Immunotherapy</i> , 2018, 10, 361-372.	2.0	15
47	Metabolomics of osteoarthritis: emerging novel markers and their potential clinical utility. <i>Rheumatology</i> , 2018, 57, 2087-2095.	1.9	35
48	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. <i>Journal of Rheumatology</i> , 2018, 45, 378-384.	2.0	45
49	Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212687.	0.9	193
50	Ustekinumab in psoriatic arthritis and related phenotypes. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 191-198.	2.5	10
51	Real-world Experience of Using <i>HLA-B*27</i> Tag-single-nucleotide Polymorphism Assay to Screen for Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1712-1712.	2.0	2
52	Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. <i>Nature Communications</i> , 2018, 9, 4178.	12.8	95
53	A review of ixekizumab in the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 993-1002.	3.0	12
54	Expression and Metabolomic Profiling in Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 51.	4.7	5

#	ARTICLE	IF	CITATIONS
55	Genetics of psoriatic arthritis. , 2018, , .		5
56	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2317-2327.	13.7	316
57	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. <i>Nature Communications</i> , 2017, 8, 15382.	12.8	251
58	Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2017, 56, 1993-2003.	1.9	121
59	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017, 26, 4301-4313.	2.9	41
60	High Accuracy and Significant Savings Using Tag-SNP Genotyping to Determine <i>HLA-B*27</i> Status. <i>Journal of Rheumatology</i> , 2017, 44, 962.2-963.	2.0	5
61	Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis. <i>BMJ Open</i> , 2016, 6, e009661.	1.9	12
62	Rat Bite Fever Resembling Rheumatoid Arthritis. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2016, 2016, 1-7.	1.9	11
63	Lysophosphatidylcholines to phosphatidylcholines ratio predicts advanced knee osteoarthritis. <i>Rheumatology</i> , 2016, 55, 1566-1574.	1.9	68
64	Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 923-935.	3.3	17
65	Genetic structure of the Newfoundland and Labrador population: founder effects modulate variability. <i>European Journal of Human Genetics</i> , 2016, 24, 1063-1070.	2.8	22
66	SMAD3 Is Upregulated in Human Osteoarthritic Cartilage Independent of the Promoter DNA Methylation. <i>Journal of Rheumatology</i> , 2016, 43, 388-394.	2.0	10
67	Metabolomic analysis of human synovial fluid and plasma reveals that phosphatidylcholine metabolism is associated with both osteoarthritis and diabetes mellitus. <i>Metabolomics</i> , 2016, 12, 1.	3.0	37
68	Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. <i>Journal of Rheumatology</i> , 2016, 43, 495-503.	2.0	32
69	Private rare deletions in <i>SEC16A</i> and <i>MAMDC4</i> may represent novel pathogenic variants in familial axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 772-779.	0.9	17
70	Overexpression of MMP13 in human osteoarthritic cartilage is associated with the SMAD-independent TGF- β 2 signalling pathway. <i>Arthritis Research and Therapy</i> , 2015, 17, 264.	3.5	37
71	Genome-wide DNA methylation study of hip and knee cartilage reveals embryonic organ and skeletal system morphogenesis as major pathways involved in osteoarthritis. <i>BMC Musculoskeletal Disorders</i> , 2015, 16, 287.	1.9	41
72	Further Evidence Supporting a Parent-of-Origin Effect in Psoriatic Disease. <i>Arthritis Care and Research</i> , 2015, 67, 1586-1590.	3.4	15

#	ARTICLE	IF	CITATIONS
73	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , 2015, 6, 7146.	12.8	220
74	Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. <i>Nature Communications</i> , 2015, 6, 7001.	12.8	156
75	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. <i>Journal of Rheumatology</i> , 2015, 42, 665-681.	2.0	42
76	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: Principles of the Management of Spondyloarthritis in Canada. <i>Journal of Rheumatology</i> , 2015, 42, 654-664.	2.0	39
77	Relationship Between Blood Plasma and Synovial Fluid Metabolite Concentrations in Patients with Osteoarthritis. <i>Journal of Rheumatology</i> , 2015, 42, 859-865.	2.0	45
78	Integrated Genomics Identifies Convergence of Ankylosing Spondylitis with Global Immune Mediated Disease Pathways. <i>Scientific Reports</i> , 2015, 5, 10314.	3.3	20
79	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2015, 386, 1137-1146.	13.7	722
80	TGF- β 2 signal transduction pathways and osteoarthritis. <i>Rheumatology International</i> , 2015, 35, 1283-1292.	3.0	60
81	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015, 373, 1329-1339.	27.0	629
82	Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 623-642.	1.9	50
83	Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. <i>Nature Genetics</i> , 2015, 47, 1085-1090.	21.4	164
84	Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. <i>American Journal of Human Genetics</i> , 2015, 97, 816-836.	6.2	245
85	Fine mapping of eight psoriasis susceptibility loci. <i>European Journal of Human Genetics</i> , 2015, 23, 844-853.	2.8	25
86	Classification of osteoarthritis phenotypes by metabolomics analysis. <i>BMJ Open</i> , 2014, 4, e006286.	1.9	90
87	Genetics of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 673-685.	3.3	39
88	Powered for Success: Considerations for Using the Candidate Gene Approach in Rheumatic Diseases in the Post-genomics Era. <i>Journal of Rheumatology</i> , 2014, 41, 1573-1575.	2.0	1
89	Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes. <i>American Journal of Human Genetics</i> , 2014, 95, 162-172.	6.2	182
90	SMAD3 Is Associated with the Total Burden of Radiographic Osteoarthritis: The Chingford Study. <i>PLoS ONE</i> , 2014, 9, e97786.	2.5	17

#	ARTICLE	IF	CITATIONS
91	Bone Morphogenetic Protein 6 Polymorphisms Are Associated with Radiographic Progression in Ankylosing Spondylitis. PLoS ONE, 2014, 9, e104966.	2.5	24
92	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet, The, 2013, 382, 780-789.	13.7	688
93	Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Human Immunology, 2013, 74, 1333-1338.	2.4	51
94	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature Genetics, 2013, 45, 730-738.	21.4	699
95	Advances in the Genetics of Spondyloarthritis and Clinical Implications. Current Rheumatology Reports, 2013, 15, 347.	4.7	11
96	Privacy protection and public goods: building a genetic database for health research in Newfoundland and Labrador. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 38-43.	4.4	4
97	TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis. Journal of Investigative Dermatology, 2012, 132, 593-600.	0.7	148
98	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 2012, 44, 1341-1348.	21.4	848
99	Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada cohort. Arthritis and Rheumatism, 2012, 64, 1119-1126.	6.7	38
100	Genome-Wide Meta-Analysis of Psoriatic Arthritis Identifies Susceptibility Locus at REL. Journal of Investigative Dermatology, 2012, 132, 1133-1140.	0.7	99
101	Rare and Common Variants in CARD14, Encoding an Epidermal Regulator of NF-kappaB, in Psoriasis. American Journal of Human Genetics, 2012, 90, 796-808.	6.2	306
102	Genome-Wide Signatures of "Rearrangement Hotspots" within Segmental Duplications in Humans. PLoS ONE, 2011, 6, e28853.	2.5	14
103	Pharmacogenetics of psoriasis. Pharmacogenomics, 2011, 12, 87-101.	1.3	24
104	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nature Genetics, 2011, 43, 761-767.	21.4	778
105	IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Annals of the Rheumatic Diseases, 2011, 70, 1594-1598.	0.9	60
106	Genetics of susceptibility and treatment response in psoriatic arthritis. Nature Reviews Rheumatology, 2011, 7, 718-732.	8.0	55
107	High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 690-694.	0.9	19
108	The Spondyloarthritis Research Consortium of Canada Registry for Spondyloarthritis. Journal of Rheumatology, 2011, 38, 1343-1348.	2.0	16

#	ARTICLE	IF	CITATIONS
109	Current Challenges in the Genetics of Psoriatic Arthritis: A Report from the GRAPPA 2009 Annual Meeting. <i>Journal of Rheumatology</i> , 2011, 38, 564-566.	2.0	2
110	Where Do We Stand With the Genetics of Psoriatic Arthritis?. <i>Current Rheumatology Reports</i> , 2010, 12, 300-308.	4.7	8
111	Update on the genetics of spondyloarthritis – ankylosing spondylitis and psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 579-588.	3.3	24
112	Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. <i>Nature Genetics</i> , 2010, 42, 991-995.	21.4	331
113	Genome-wide association analysis identifies three psoriasis susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 1000-1004.	21.4	313
114	Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity of Methotrexate in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1508-1512.	2.0	45
115	Pathophysiology and Pathogenesis of Immune-Mediated Inflammatory Diseases: Commonalities and Differences. <i>Journal of rheumatology Supplement, The</i> , 2010, 85, 11-26.	2.2	33
116	Association of Interleukin 23 Receptor Variants with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 137-140.	2.0	72
117	IL-23R Polymorphisms in Patients with Ankylosing Spondylitis in Korea: Table 1.. <i>Journal of Rheumatology</i> , 2009, 36, 1003-1005.	2.0	42
118	Genome-wide scan reveals association of psoriasis with IL-23 and NF- κ B pathways. <i>Nature Genetics</i> , 2009, 41, 199-204.	21.4	1,229
119	An Autoinflammatory Disease with Deficiency of the Interleukin-1 α Receptor Antagonist. <i>New England Journal of Medicine</i> , 2009, 360, 2426-2437.	27.0	892
120	Association of interleukin-23 receptor variants with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1020-1025.	6.7	152
121	A variant of the IL4 150V single nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2207-2208.	6.7	17
122	Psoriatic arthritis: genetic susceptibility and pharmacogenetics. <i>Pharmacogenomics</i> , 2008, 9, 195-205.	1.3	13
123	Variability of haplotype phase and its effect on genetic analysis. <i>Canadian Conference on Electrical and Computer Engineering</i> , 2008, , .	0.0	0
124	Genetics of psoriasis and psoriatic arthritis: update and future direction. <i>Journal of Rheumatology</i> , 2008, 35, 1449-53.	2.0	79
125	Genetics of ankylosing spondylitis: An update. <i>Current Rheumatology Reports</i> , 2007, 9, 383-389.	4.7	7
126	Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies. <i>Nature Genetics</i> , 2006, 38, 556-560.	21.4	227

#	ARTICLE	IF	CITATIONS
127	Association of the L1 gene cluster with susceptibility to ankylosing spondylitis: An analysis of three Canadian populations. <i>Arthritis and Rheumatism</i> , 2006, 54, 974-985.	6.7	69
128	Association between the interleukin-1 family gene cluster and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2321-2325.	6.7	114
129	The Newfoundland population: a unique resource for genetic investigation of complex diseases. <i>Human Molecular Genetics</i> , 2003, 12, R167-R172.	2.9	83
130	Probing for genes in seronegative spondyloarthropathy. <i>Current Rheumatology Reports</i> , 2000, 2, 306-310.	4.7	1
131	Immunogenetic profile of patients with psoriatic arthritis varies according to the age at onset of psoriasis. <i>Arthritis and Rheumatism</i> , 1999, 42, 818-823.	6.7	94
132	Excessive paternal transmission in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1228-1231.	6.7	78